SAKAR2025-04-012025-06-30SAKAR2025-04-012025-06-30in-capmkt:OtherExpenses1MemberSAKAR2025-04-012025-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares000000SAKARNOTLISTEDINE732S01012Sakar Healthcare LimitedMain BoardEquity2025-04-012026-03-312025-07-252025-07-21INRLakhsQuarterlyFirst quarterSingle segmentPharmaceuticals2025-07-2511:30:002025-07-2512:10:00Not applicable2025-04-012025-06-30UnauditedConsolidated5273620003939000531301000287573000019510007549600021426000557230003528400047745300053848000053848000071350007135000046713000000046713000-26700046446000222499000102.112.11002.112.11For Quarter ended 30-06-2025, the Current tax is Rs. 90.29 lacs and MAT Credit Entitlement is Rs. (90.29 lacs) hence the net effect is NIL <BR> <BR> 1. The Company is operating only in one segment. Hence segment reporting is not given. <BR> 2. The consolidated Unaudited financial results of the Company are comprising of its subsidiary M/s. Sakar Oncology Private Limited. <BR> 3. The Consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34 “Interim Financial Reporting” as prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. <BR> 4. Provision for taxation/deferred taxation, if any, will be made at the year end. <BR> 5. Figures, wherever required, are regrouped / rearranged. <BR> 6. The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 25th July 2025 <BR> 7. The Company has allotted 3,00,000 Equity Shares to Non-Promoters on conversion of Convertible Warrants in to Equity on Preferential Basis on 17th June 2025Other Expenses35284000Re-measurement gains/(losses) on defined benefit plans-370000-370000-1030000-267000